A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal

Area of Science:

• Ophthalmology
• Dry Eye Disease Research
• Ophthalmic Solutions

Background:

• Dry Eye Disease (DED) is a prevalent condition impacting quality of life.
• Conventional treatments for DED often yield suboptimal patient responses.
• A novel ophthalmic solution with Ribohyal (riboflavin-hyaluronic acid complex) was investigated for DED management.

Purpose of the Study:

• To evaluate the real-world efficacy of Lacrinova eye drops in DED patients.
• To assess the tolerability and patient adherence to the Ribohyal-based ophthalmic solution.
• To analyze the impact of the novel therapy on DED symptoms and clinical parameters.

Main Methods:

• A national survey involving 2993 adult patients diagnosed with DED.
• Patients were treated with Lacrinova eye drops four times daily for three months.
• Outcomes measured included patient-reported symptoms, visual acuity, tear film break-up time, and corneal staining.

Main Results:

• Significant improvements observed in all nine symptom domains (53-60% reduction).
• Best-corrected visual acuity (BCVA) and tear break-up time (BUT) showed significant improvement.
• Corneal fluorescein staining (CFS) prevalence decreased from 42.0% to 23.4%.

Conclusions:

• Lacrinova eye drops containing Ribohyal demonstrated significant efficacy in improving DED symptoms and clinical signs.
• The treatment exhibited excellent tolerability and high patient adherence in a real-world setting.
• Findings support Lacrinova as a viable therapeutic option for DED, with further controlled studies recommended.